4.7 Article

Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses

Journal

ANTIVIRAL RESEARCH
Volume 84, Issue 3, Pages 254-259

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2009.09.012

Keywords

Herpes simplex virus; Human cytomegalovirus; Murine cytomegalovirus; Vaccinia virus; Cowpox virus; Ectromelia virus; Acyclic nucleoside phosphonates; Alkoxyalkyl prodrugs; Drug delivery

Funding

  1. NIH [AI-071803, AI-074057, EY-07366]
  2. National Institute for Allergy and Infectious Disease
  3. Center for AIDS and HIV Research of the San Diego VA Healthcare System
  4. N.I.H., National Institutes of Allergy and Infectious Disease [NO1-AI-30049, NO1-AI-15436]
  5. NATIONAL EYE INSTITUTE [R01EY007366] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI074057, R01AI071803, R01AI066499] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Our previous studies showed that esterification of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine (HPMPA) or 1-(S)-[3-hydroxy-2-(phosphonomethoxy)-propyl]cytosine (HPMPC) with alkoxyalkyl groups such as hexadecyloxypropyl (HDP) or octadecyloxyethyl (ODE) resulted in large increases in antiviral activity and oral bioavailability. The HDP and ODE esters of HPMPA were shown to be active in cells infected with human immunodeficiency virus, type 1 (HIV-1), while HPMPA itself was virtually inactive. To explore this approach in greater detail, we synthesized four new compounds in this series, the ODE esters of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine (HPMPG), 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]thymine (HPMPT), 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2-amino-6-cyclopropylaminopurine (HPMP-cPrDAP) and evaluated their antiviral activity against herpes simplex virus, type I (HSV-1), human cytomegalovirus (HCMV), and vaccinia, cowpox and ectromelia. Against HSV-1, subnanomolar EC50 values were observed with ODE-H]PMPA and ODE-HPMPC while ODE-HPMPG had intermediate antiviral activity with an EC50 of 40 nM. In HFF cells infected with HCMV, the lowest EC50 values were observed with ODE-HPMPC, 0.9 nM. ODE-HPMPA was highly active with an EC50 of 3 nM, while ODE-HPMPG and ODE-HPMPDAP were also highly active with EC(50)s of 22 and 77 nM, respectively. Against vaccinia and cowpox viruses, ODE-HPMPG and ODE-HPMPDAP were the most active and selective compounds' with EC50 values of 20-60 nM and selectivity index values of 600-3500. ODE-HPMPG was also active against ectromelia virus with an EC50 value of 410 nM and a selectivity index value of 166. ODE-HPMPG and ODE-HPMPDAP are proposed for further preclinical evaluation as possible candidates for treatment of HSV, HCMV or orthopoxvirus diseases. (C) 2009 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Chemistry, Medicinal

Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA Amplification

James R. Beadle, Nadejda Valiaeva, Guang Yang, Jei-Hwa Yu, Thomas R. Broker, Kathy A. Aldern, Emma A. Harden, Kathy A. Keith, Mark N. Prichard, Tracy Hartman, Robert W. Buckheit, Louise T. Chow, Karl Y. Hostetler

JOURNAL OF MEDICINAL CHEMISTRY (2016)

Article Oncology

Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates

Kevin A. Cassady, David F. Bauer, Justin Roth, Melissa R. Chambers, Trent Shoeb, Jennifer Coleman, Mark Prichard, G. Yancey Gillespie, James M. Markert

MOLECULAR THERAPY-ONCOLYTICS (2017)

Article Pharmacology & Pharmacy

USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses

Karoly Toth, Jacqueline F. Spencer, Baoling Ying, Ann E. Tollefson, Caroll B. Hartline, Eric T. Richar, Jiajun Fan, Jinglei Lyu, Boris A. Kashemirov, Cheryl Harteg, Dawn Reyna, Elke Lipka, Mark N. Prichard, Charles E. McKenna, William S. M. Wold

ANTIVIRAL RESEARCH (2018)

Article Pharmacology & Pharmacy

Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis

Debra C. Quenelle, Alexander Birkmann, Thomas Goldner, Tamara Pfaff, Holger Zimmermann, Susanne Bonsmann, Deborah J. Collins, Terri L. Rice, Mark N. Prichard

ANTIVIRAL RESEARCH (2018)

Article Pharmacology & Pharmacy

Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures

N. Sanjib Banerjee, Hsu-Kun Wang, James R. Beadle, Karl Y. Hostetler, Louise T. Chow

ANTIVIRAL RESEARCH (2018)

Article Pharmacology & Pharmacy

Inhibition of adenovirus serotype 14 infection by octadecyloxyethyl esters of (S)-[(3-hydroxy-2-phosphonomethoxy)propyl]- nucleosides in vitro

Yohichi Kumaki, John D. Woolcott, Jason P. Roth, Tyler Z. Mclean, Donald F. Smee, Dale L. Barnard, Nadejda Valiaeva, James R. Beadle, Karl Y. Hostetler

ANTIVIRAL RESEARCH (2018)

Article Pharmacology & Pharmacy

New therapies for human cytomegalovirus infections

William J. Britt, Mark N. Prichard

ANTIVIRAL RESEARCH (2018)

Article Medicine, Research & Experimental

Xenotransplantation panel for the detection of infectious agents in pigs

Caroll B. Hartline, Ra'Shun L. Conner, Scott H. James, Jennifer Potter, Edward Gray, Jose Estrada, Mathew Tector, A. Joseph Tector, Mark N. Prichard

XENOTRANSPLANTATION (2018)

Article Pharmacology & Pharmacy

A standardized approach to the evaluation of antivirals against DNA viruses: Orthopox-, adeno-, and herpesviruses

Caroll B. Hartline, Kathy A. Keith, Jessica Eagar, Emma A. Harden, Terry L. Bowlin, Mark N. Prichard

ANTIVIRAL RESEARCH (2018)

Article Pharmacology & Pharmacy

A standardized approach to the evaluation of antivirals against DNA viruses: Polyomaviruses and lymphotropic herpesviruses

Kathy A. Keith, Caroll B. Hartline, Terry L. Bowlin, Mark N. Prichard

ANTIVIRAL RESEARCH (2018)

Article Pharmacology & Pharmacy

Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate

James R. Beadle, Kathy A. Aldern, Xing-Quan Zhang, Nadejda Valiaeva, Karl Y. Hostetler, Robert T. Schooley

ANTIVIRAL RESEARCH (2019)

Article Microbiology

Broad-Spectrum In Vitro Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524)

Michael K. Lo, Punya Shrivastava-Ranjan, Payel Chatterjee, Mike Flint, James R. Beadle, Nadejda Valiaeva, Joyce Murphy, Robert T. Schooley, Karl Y. Hostetler, Joel M. Montgomery, Christina F. Spiropoulou

Summary: The intravenous administration of remdesivir limits its use in treating COVID-19, while ODBG-P-RVn, an orally available prodrug with broad-spectrum antiviral activity, shows potential therapeutic effects and warrants further in vivo evaluation. This study highlights the importance of optimizing drug delivery to combat emerging viruses and diseases.

MICROBIOLOGY SPECTRUM (2021)

Article Pharmacology & Pharmacy

A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation

Mei Chen, Jiangping Hou, Guilin Tan, Peng Xie, William R. Freeman, James R. Beadle, Karl Y. Hostetler, Lingyun Cheng

DRUG DELIVERY (2017)

Article Pharmacology & Pharmacy

Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies

Donald F. Smee, Mark N. Prichard

ANTIVIRAL RESEARCH (2017)

Article Oncology

Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia

Haytham Khoury, Ruijuan He, Aaron Schimmer, James R. Beadle, Karl Y. Hostetler, Mark D. Minden

CHEMOTHERAPY (2018)

No Data Available